Resource Summary Report

Generated by NIF on Apr 20, 2025

Genentech

RRID:SCR_003997

Type: Tool

Proper Citation

Genentech (RRID:SCR_003997)

Resource Information

URL: http://www.gene.com/

Proper Citation: Genentech (RRID:SCR_003997)

Description: A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or lifethreatening medical conditions.

Abbreviations: Genentech

Synonyms: Genentech Inc, F. Hoffmann-La Roche Ltd / Genentech

Resource Type: commercial organization

Keywords: drug, genetic, medicine, biotechnology, oncology, immunology, tissue growth, tissue repair, neuroscience, infectious disease, microbiology, medical imaging

Related Condition: Infectious disease, Cancer

Funding:

Resource Name: Genentech

Resource ID: SCR_003997

Alternate IDs: nlx_158417

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250420T014202+0000

Ratings and Alerts

No rating or validation information has been found for Genentech.

No alerts have been found for Genentech.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 3216 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Kottana RK, et al. (2025) A method to quantitatively characterize the formation and dissociation of tumor cell clusters using light transmission aggregometry. Molecular oncology, 19(1), 37.

Pourmal S, et al. (2025) Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture. Nature, 637(8045), 446.

Haap-Hoff A, et al. (2025) RNAi library screening reveals G?1, Casein Kinase 2 and ICAP-1 as novel regulators of LFA-1-mediated T?cell polarity and migration. Immunology and cell biology, 103(1), 73.

Angelicola S, et al. (2025) PD-L1 and IFN-? modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD). Journal of translational medicine, 23(1), 2.

Lopez J, et al. (2025) Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature medicine, 31(1), 152.

Scalambra L, et al. (2025) Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. Journal of translational medicine, 23(1), 136.

Xie Y, et al. (2025) Sonothrombolysis Using Microfluidically Produced Microbubbles in a Murine Model of Deep Vein Thrombosis. Annals of biomedical engineering, 53(1), 109.

Wang L, et al. (2025) The impact of bevacizumab intraperitoneal perfusion combined with paclitaxel and platinum-based chemotherapy on serum stromal-derived factor-1? (SDF-1?) and chemokine ligand 5 (CXCL-5) levels in patients with ovarian cancer after tumor cell debulking surgery. Anti-cancer drugs, 36(3), 232.

Duan A, et al. (2025) The antiarthritic effect of CBR-470-1 in hypoxic environment is to

increase the level of NOD-like receptor family pyrin domain containing 3 ubiquitination by decreasing phosphoglycerate kinase 1 activity. Clinical and translational medicine, 15(1), e70118.

Tang S, et al. (2025) Ultrasound-Guided Histotripsy Triggers the Release of Tumor-Associated Antigens from Breast Cancers. Cancers, 17(2).

Brod M, et al. (2025) Development and validation of the Child Hemophilia Treatment Experience Measure: A new observer-reported outcome measure. Haemophilia: the official journal of the World Federation of Hemophilia, 31(1), 48.

Nguyen A, et al. (2025) Structural and functional characterization of integrin ?5-targeting antibodies for anti-angiogenic therapy. bioRxiv: the preprint server for biology.

Maier A, et al. (2025) Predicting purification process fit of monoclonal antibodies using machine learning. mAbs, 17(1), 2439988.

Chowdhury NN, et al. (2024) Plasminogen deficiency suppresses pancreatic ductal adenocarcinoma disease progression. Molecular oncology, 18(1), 113.

Muñoz García A, et al. (2024) Single-cell transcriptomics reveals a role for pancreatic duct cells as potential mediators of inflammation in diabetes mellitus. Frontiers in immunology, 15, 1381319.

Gracia-Hernandez M, et al. (2024) Targeting HDAC6 improves anti-CD47 immunotherapy. Journal of experimental & clinical cancer research: CR, 43(1), 60.

Ma C, et al. (2024) Gasdermin D in macrophages drives orchitis by regulating inflammation and antigen presentation processes. EMBO molecular medicine, 16(2), 361.

Han LW, et al. (2024) A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGF?3 Antibody, in Healthy Volunteers. Rheumatology and therapy, 11(3), 755.

Watts E, et al. (2024) Enhanced Characterization of Lysine-Linked Antibody Drug Conjugates Enabled by Middle-Down Mass Spectrometry and Higher-Energy Collisional Dissociation-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation and Ultraviolet Photodissociation. Antibodies (Basel, Switzerland), 13(2).

Launder D, et al. (2024) Immunity to pathogenic mucosal C. albicans infections mediated by oral megakaryocytes activated by IL-17 and candidalysin. Mucosal immunology, 17(2), 182.